Business
Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp
NEWPORT BEACH, Calif., August 25, 2025--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline results from a U.S. pivotal study of Evolysse™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume.
About this update from Evolus, Inc. Common Stock
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/996893c2aaa65e8c4cb60bb0826902db"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5Wt3P472ms0uW9iJnNB0rA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/996893c2aaa65e8c4cb60bb0826902db","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/iMms0ivRoODlYj6MmIpt0A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/996893c2aaa65e8c4cb60bb0826902db","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Evolysse™ Sculpt met the primary endpoint of non-inferiority and demonstrated statistical superiority to Restylane®-Lyft","length":120,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The safety profile was similar between Evolysse™ Sculpt and Restylane®-Lyft and no treatment-related serious adverse events","length":123,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Premarket Approval application submitted to the U.S. Food and Drug Administration; Approval expected in the second half of 2026","length":127,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":370,"olType":false},{"type":"text","content":"NEWPORT BEACH, Calif., August 25, 2025--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline results from a U.S. pivotal study of Evolysse™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume.","length":354,"tagName":"p"},{"type":"text","content":""Achieving positive topline results in our mid-face study is an important milestone for Evolus as we expand beyond Jeuveau® with the Evolysse™ line," said David Moatazedi, President and Chief Executive Officer. "Evolysse™ Sculpt, the flagship brand in the Evolysse™ collection, targets the highest-value segment of today’s dermal filler market and is among the few products currently indicated for the mid-face area. Its strong performance reinforces our strategy to build a leading performance beauty com...